BioSpace News Archive

The global intraocular lens market is expected to be on course to achieve considerable growth in the coming years of the forecast period.

MicroPort Scientific Corporation announced that MicroPort Cardiac Rhythm Management Limited, which is MicroPort®'s subsidiary focused on developing and commercializing implantable pacemaker and defibrillator devices and related technologies to manage cardiac rhythm disorders, has entered into definitive agreements in connection with its Series C financing with total investment proceeds of US$150 million.

BrainStorm Cell Therapeutics Inc., a leading developer of cellular therapies for neurodegenerative diseases, announced that is has received Good Manufacturing Practice approval from the Israel Ministry of Health for three state-of-the-art cleanrooms leased by the Company at the Tel Aviv Sourasky Medical Center in Tel Aviv, Israel.

Centene Corporation announced its financial results for the second quarter ended June 30, 2021, reporting diluted loss per share of $ and adjusted diluted earnings per share of $1.25.

Centogene N.V., a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, announced the appointment of Dr. Patrice P. Denèfle as Chief Scientific Officer.

Amicus Therapeutics announced that the Company will host a conference call and live audio webcast on Thursday, August 5, 2021 at 8:30 a.m. ET to discuss financial results for the second quarter ended June 30, 2021.

Tonix Pharmaceuticals Holding Corp. announced the signing of a Purchase and Sale Agreement to acquire an approximately 48,000 square foot research and development facility in Frederick, MD to support Tonix’s expanding infectious disease pipeline, including TNX-1800, a live replicating viral vaccine designed to protect against COVID-19, TNX-801, a live vaccine designed to protect against smallpox and monkeypox, and TNX-3500, a small molecule antiviral to inhibit replication of SARS-CoV-2.

Harmony Biosciences Holdings, Inc., a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, announced that it will issue a press release on the Company’s second quarter 2021 financial results on Tuesday, August 10, 2021 at 8:00 a.m. ET.

BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers with clear genetic drivers, today announced a non-exclusive, co-funded clinical collaboration with Bristol Myers Squibb to evaluate the combination of BBP-398, a potentially best-in-class SHP2 inhibitor, with OPDIVO® (nivolumab)

iXensor Co., Ltd. (6734.TWO) launches the next generation of integrated COVID-19 screening solution, the PixoHealth Pass Admin App and Web Portal.